Acquired
MET
Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
JCO Precis Oncol
.
2019:3:PO.19.00011.
doi: 10.1200/PO.19.00011.
Epub 2019 May 10.
Authors
Ken Suzawa
1
,
Michael Offin
1
,
Adam J Schoenfeld
1
,
Andrew J Plodkowski
1
,
Igor Odintsov
1
,
Daniel Lu
2
,
William W Lockwood
2
,
Maria E Arcila
1
,
Charles M Rudin
1
,
Alexander Drilon
1
,
Helena A Yu
1
,
Gregory J Riely
1
,
Romel Somwar
1
,
Marc Ladanyi
1
Affiliations
1
Memorial Sloan Kettering Cancer Center, New York, NY.
2
University of British Columbia, Vancouver, British Columbia, Canada.
PMID:
31157314
PMCID:
PMC6541452
DOI:
10.1200/PO.19.00011
No abstract available
Grants and funding
P01 CA129243/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
R25 CA020449/CA/NCI NIH HHS/United States
T32 CA009207/CA/NCI NIH HHS/United States